AMPK: a therapeutic target of heart failure-not only metabolism regulation

Xuan Li1, Jia Liu1,2, Qingguo Lu1,3

  • 1Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS 39216, U.S.A.

Bioscience Reports
|December 6, 2018
PubMed

Insights

AMP-activated protein kinase (AMPK) offers cardioprotection by improving heart energy supply and regulating physiological processes. Activating AMPK may hold promise for treating heart failure (HF), warranting further clinical investigation.

Area of Science:

  • Biochemistry
  • Cardiology
  • Molecular Biology

Background:

  • Heart failure (HF) is a growing global health concern with high mortality rates.
  • Various cardiovascular diseases contribute to HF by disrupting physiological functions.
  • AMP-activated protein kinase (AMPK), a key cellular energy sensor, exhibits significant cardioprotective properties.

Purpose of the Study:

  • To review the role of AMPK in heart failure pathophysiology.
  • To highlight AMPK's mechanisms in improving cardiac energy metabolism and function.
  • To discuss potential AMPK-targeting therapies for heart failure.

Main Methods:

  • Literature review focusing on AMPK's role in cardiovascular health.
  • Analysis of AMPK's impact on ATP production and physiological regulation in the heart.
  • Evaluation of existing and potential clinical drugs targeting AMPK activation.

Main Results:

  • AMPK enhances ATP production, boosting energy supply in failing hearts.
  • AMPK activation regulates critical physiological processes essential for restoring heart function.
  • Several drugs influencing AMPK show potential therapeutic value for HF.

Conclusions:

  • AMPK activation presents a promising strategy for managing heart failure.
  • Further clinical trials are crucial to validate AMPK manipulation for HF treatment.
  • Targeting AMPK could offer a novel therapeutic avenue for cardiovascular diseases.

Related Concept Videos

Regulation of Metabolism01:19

Regulation of Metabolism

Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
11.6K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
933
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.7K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
888
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
339
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
968